PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-22.30%
Both yoy net incomes decline, with AGEN at -54.88%. Martin Whitman would view it as a broader sector or cyclical slump hitting profits.
24.17%
D&A growth well above AGEN's 7.89%. Michael Burry would suspect heavier depreciation burdens that might erode net income unless top-line follows suit.
100.00%
Lower deferred tax growth vs. AGEN's 24892.09%, implying fewer future tax liabilities. David Dodd would confirm there’s no short-term tax shock instead.
-9.33%
Both cut yoy SBC, with AGEN at -58.74%. Martin Whitman would view it as an industry shift to reduce stock-based pay or a sign of reduced expansions.
-80.33%
Both reduce yoy usage, with AGEN at -728.82%. Martin Whitman would find an industry or cyclical factor prompting leaner operational approaches.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-46.04%
Both negative yoy AP, with AGEN at -539.91%. Martin Whitman would find an overall trend toward paying down supplier credit in the niche.
-249.09%
Both reduce yoy usage, with AGEN at -1337.98%. Martin Whitman would suspect an industry or cyclical factor pulling back on these items.
-101.42%
Negative yoy while AGEN is 654.74%. Joel Greenblatt would see a near-term net income or CFO stability advantage unless competitor invests or writes down more aggressively.
-72.30%
Both yoy CFO lines are negative, with AGEN at -55.60%. Martin Whitman would suspect cyclical or cost factors harming the entire niche’s cash generation.
-455.28%
Both yoy lines negative, with AGEN at -98.28%. Martin Whitman would suspect a cyclical or broad capital spending slowdown in the niche.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
100.00%
We have some outflow growth while AGEN is negative at -99.90%. John Neff sees competitor possibly pulling back more aggressively from minor expansions or intangible invests.
-427.62%
Both yoy lines negative, with AGEN at -135.08%. Martin Whitman suspects a broader cyclical shift away from heavy investing across the niche.
No Data
No Data available this quarter, please select a different quarter.
53916.27%
Stock issuance far above AGEN's 179.32%. Michael Burry flags a significant dilution risk vs. competitor’s approach unless ROI is very high.
No Data
No Data available this quarter, please select a different quarter.